Glioblastoma (GBM), one of the most aggressive types of brain cancer, is one of the greatest challenges for medicine, both ...
Europe’s drug regulatory agency has given Kizfizo a negative opinion for the second time, following one from November 2024.
WarwickshireWorld on MSN4d
Brindley Twist Tafft and James steps in to offer support to patients affected by extended use of temozolomide chemotherapyCoventry and Warwickshire’s leading medical negligence practitioners, is offering its professional support to patients ...
Orphelia Pharma is exploring alternative regulatory pathways for KIZFIZO after receiving a negative opinion from the ...
As previously disclosed on November 14, 2024, Allarity’s (ALLR) cash position is expected to support operations into 2026. The $2.5 million ...
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib-a differentiated ...
Australasian Gastrointestinal Trials Group (AGITG) CONTROL NET Study: Phase II study evaluating the activity of 177 Lu-Octreotate peptide receptor radionuclide therapy (LuTate PRRT) and capecitabine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback